Patents Examined by Blondel Hazel
  • Modified (1-56) beta interferons
    Patent number: 4793995
    Abstract: Modified beta interferons containing amino acid substitutions in the beta interferon amino acids 1 to 56 are described. These modified beta interferons exhibit changes in the antiviral, cell growth regulatory or immunomodulatory activities when compared with unmodified beta interferon.
    Type: Grant
    Filed: June 22, 1984
    Date of Patent: December 27, 1988
    Assignee: G. D. Searle & Co.
    Inventors: Leslie D. Bell, John C. Smith, Paul G. Boseley
  • Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
    Patent number: 4792447
    Abstract: Highly specific antibodies directed against immunoglobulin determinants coupled to one or more toxin molecules provide antibody-toxin conjugates which are useful in selectively inhibiting the growth of target immunoglobulin generating cells. The antibody-toxin conjugate consists of an antibody specific for a selected immunoglobulin determinant including isotypic, allotypic or idiotypic variable determinants, coupled to one or more toxin molecules. Anti-idiotype toxin conjugates are provided which have specificity which distinguishes B cell tumor cells from normal B cells. Also disclosed is an antibody-toxin conjugate consisting of anti-IgD A chain. The antibody-toxin conjugate is used as a cell or tumor specific cytotoxic agent directed selectively against those cells expressing the corresponding immunoglobulin to which the antibody portion has specificity.
    Type: Grant
    Filed: May 27, 1983
    Date of Patent: December 20, 1988
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan W. Uhr, Ellen S. Vitetta
  • Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique
    Patent number: 4783402
    Abstract: A process for producing a primary or secondary alcohol derivative of a phosopholipid which comprises reacting the phospholipid with a primary or secondary alcohol in the presence of phospholipase DM.
    Type: Grant
    Filed: April 10, 1984
    Date of Patent: November 8, 1988
    Assignee: Meito Sangyo Kabushiki Kaisha
    Inventors: Yoshitaka Kokusho, Shigeaki Kato, Haruo Machida
  • Novel 5-substituted 2-pyrimidinone nucleosides and methods of use
    Patent number: 4782142
    Abstract: Compounds for inhibiting the replication of DNA viruses which induce the formation of thymidine kinase enzyme of the formula: ##STR1## wherein R.sub.1 is a radical selected from the group consisting of chloro, iodo, hydroxy, alkoxyalkyl, hydroxyalkyl, methylamino, formyl, nitro, and unsubstituted hydrocarbon groups of 2 to about 3 carbon atoms or halosubstituted hydrocarbon groups of 1 to about 3 carbon atoms; R.sub.2 is hydrogen or hydroxy; and R.sub.3 is hydroxy, --OP(O)(OH).sub.2, amino, or --OCOR.sub.4 where R.sub.4 is alkyl or alkoxyalkyl of 2 to about 18 carbon atoms.
    Type: Grant
    Filed: August 20, 1984
    Date of Patent: November 1, 1988
    Assignee: The Research Foundation of State University of New York
    Inventors: Thomas J. Bardos, Yung-Chi Cheng, Alan C. Schroeder, Simon M. N. Efange
  • Enzymatic production of sphingophospholipid derivatives
    Patent number: 4782019
    Abstract: A process for producing a sphingophospholipid derivative comprising reacting a sphingophospholipid with a specified compound having an alcoholic hydroxyl group selected from the group consisting of specified primary alcohol compounds, specified secondary alcohol compounds and specified saccharides or their phenol glycosides in the presence of phospholipase DM.
    Type: Grant
    Filed: April 10, 1984
    Date of Patent: November 1, 1988
    Assignee: Meito Sangyo Kabushiki Kaisha
    Inventors: Yoshitaka Kokusho, Shigeaki Kato, Haruo Machida
  • Novel interferon alphas
    Patent number: 4780530
    Abstract: Novel IFN.alpha.S51B10 and IFN.alpha.S17H9 of this invention are prepared from BALL-1 cell induced with Sendai virus according to the well known recombinant DNA technique. Further, this invention relates to a DNA encoding interferon .alpha.S51B10 or .alpha.S17H9, a recombinant plasmid enabling an expression of interferon .alpha.S51B10 or .alpha.S17H9 in a host microorganism and a microorganism transformed by the recombinant plasmid. These two IFN.alpha.s have antiviral and anti-tumor activity as other subtypes of IFN.alpha. and are useful as medicines for human and animal.
    Type: Grant
    Filed: August 8, 1985
    Date of Patent: October 25, 1988
    Assignee: Shionogi & Co., Ltd.
    Inventors: Hiroshi Teraoka, Kosaburo Sato, Kentaro Tanaka
  • Production of antiviral agents
    Patent number: 4780413
    Abstract: An improvement to the process for the production of interferon by adding an inducer to lymphoblastoid cells susceptible to being induced to produce interferon is described wherein the cells are treated with an enhancing agent at, or following, induction. In a preferred aspect the cells are also pretreated, before induction, with a stimulator.
    Type: Grant
    Filed: August 26, 1985
    Date of Patent: October 25, 1988
    Assignee: Burroughs Wellcome Co.
    Inventor: Michael D. Johnston
  • Immunodominant epitope of the circumsporozoite surface protein
    Patent number: 4769235
    Abstract: Disclosed are peptides the sequence of which defines an immunodominant epitope from the repetitive immunodominant epitope region of the circumsporozoite (CS) protein of a member of the genus Plasmodium, the sequence of the peptide being shorter in length than the repeating unit of the CS protein.
    Type: Grant
    Filed: January 28, 1985
    Date of Patent: September 6, 1988
    Assignee: New York University
    Inventors: David H. Schlesinger, Victor N. Nussenzweig
  • Structure and properties of modified interferons
    Patent number: 4769233
    Abstract: A composition of matter comprising a polypeptide of the formula:A-R.sub.1 -B-R.sub.2-22.sup.-Cwherein:A is the amino acid sequence 1-16 of human beta interferon;R.sub.1 is cysteine, serine or alanine;B is the amino acid sequence 18-31 of human beta interferon;R.sub.2-22 are naturally occurring amino acids;C is the amino acid sequence 53-166 of human beta interferon.
    Type: Grant
    Filed: May 3, 1985
    Date of Patent: September 6, 1988
    Assignee: G. D. Searle & Co.
    Inventors: Leslie D. Bell, Paul G. Boseley, Alan G. Porter
  • Expression linkers
    Patent number: 4769326
    Abstract: The present invention is based upon a general principle of providing specific oligonucleotide segments ("linkers", herein) to be attached in sequence to a cloned DNA coding segment. The linkers of the present invention confer desired functional properties on the expression of the protein coded by the coding sequence. Using linkers of the present invention, the desired protein may be expressed either as a fusion or non-fusion protein. A linker coding for an additional sequence of amino acids may be attached, the sequence being chosen to provide properties exploitable in a simplified purification process. A linker coding for an amino acid sequence of the extended specific cleavage site of a proteolytic enzyme is provided, as well as specific cleavage linkers for simpler specific cleavage sites.
    Type: Grant
    Filed: April 12, 1984
    Date of Patent: September 6, 1988
    Assignee: The Regents of the University of California
    Inventor: William J. Rutter
  • Vaccine against varicella-zoster virus
    Patent number: 4769239
    Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified through DNA sequence analysis. Fragments of the DNA have been cloned into a vector which, when placed into a host organism, expresses proteins which react with human convalescent zoster sera and with monoclonal antibodies which neutralize viral infectivity. These proteins are useful for preparation of a vaccine for VZV.
    Type: Grant
    Filed: August 21, 1984
    Date of Patent: September 6, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Ronald W. Ellis, Paul M. Keller
  • Solubilization of proteins for pharmaceutical compositions using polymer conjugation
    Patent number: 4766106
    Abstract: A pharmaceutical composition is prepared wherein a biologically active conjugated protein which is .beta.-interferon, interleukin-2, or an immunotoxin is dissolved in an aqueous carrier medium without the presence of a solubilizing agent. The unconjugated protein, which is not water-soluble or not readily soluble in water at pH 6-8 without such solubilizing agent, is selectively conjugated to a water-soluble polymer selected from polyethylene glycol homopolymers or polyoxyethylated polyols.
    Type: Grant
    Filed: January 25, 1988
    Date of Patent: August 23, 1988
    Assignee: Cetus Corporation
    Inventors: Nandini Katre, Michael J. Knauf
  • Live vaccine for bovine babesiosis
    Patent number: 4762711
    Abstract: A live vaccine for bovine babesiosis comprises viable bovine erythrocytes parasitized with a cloned population of Babesia bovis, the clone strain being fast-growing, avirulent, and producing a mild but immunizing infection when administered. The vaccine is free of slow-growing virulent B. bovis. The clone strain used in the vaccine is prepared from a natural mixture of virulent and avirulent babesia by progressive dilution culturing to obtain cultures containing single parasites, propagating the single parasites under favorable conditions for growth, and selecting a fast-growing avirulent clone line for either in vitro or in vivo propagation to prepare the vaccines.
    Type: Grant
    Filed: February 25, 1986
    Date of Patent: August 9, 1988
    Assignee: The Curators of the University of Missouri
    Inventors: Gerald M. Buening, Charles A. Carson
  • Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
    Patent number: 4762713
    Abstract: This invention relates to immunogenic conjugates of capsular polymers or polymer fragments from bacterial pathogens and bacterial toxins, toxoids or subunits. The invention also relates to methods for the preparation of the conjugates and a vaccine containing the conjugates which elicits effective levels of anti-capsular polymer antibodies in human infants. Also disclosed are methods for inducing active immunization against systemic infection in human infants caused by bacterial pathogens, by administering an effective amount of the above-described conjugate, followed by the capsular polymer fragments alone.
    Type: Grant
    Filed: May 8, 1985
    Date of Patent: August 9, 1988
    Assignee: The University of Rochester
    Inventor: Porter W. Anderson
  • Cancer therapy with interferon
    Patent number: 4762705
    Abstract: The effectiveness of interferon for treatment against cancer may be increased by first administering an agent for inhibiting tyrosinase. In this manner the tyrosinase which is known to be produced by malignancies, and which may cause inactivation of the interferon, will be substantially inactivated prior to the interferon administration.
    Type: Grant
    Filed: March 29, 1984
    Date of Patent: August 9, 1988
    Assignees: Adolf W. Schwimmer, Irwin Steven Schwartz, David Rubin
    Inventor: David Rubin
  • New conjugates associating, by covalent bond, an enzyme with an antibody, and medicinal associations using the said conjugates
    Patent number: 4762707
    Abstract: The present invention relates to new immunoenzymic conjugates resulting from a chemical coupling, by covalent bond, of an antibody or a fragment of antibody, which has retained the capacity of recognizing the selected antigen, with an enzyme capable of producing ammonium ions from natural substrates which are well tolerated in higher animal organisms.The invention also relates to a process for the preparation of these conjugates and the medicinal associations of said conjugates with an immunotoxin.
    Type: Grant
    Filed: May 21, 1985
    Date of Patent: August 9, 1988
    Assignee: Sanofi (Societe Anonyme)
    Inventors: Franz Jansen, Pierre Gros
  • Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
    Patent number: 4762712
    Abstract: A process for the production of a polyvalent vaccine effective in the prevention and treatment of mastitis in bovine animals is disclosed, which comprises periodically culturing the milk of animals exhibiting preclinical mastitis to cultivate any pathogens present therein, killing those pathogens and incorporating each strain of cultivated, killed pathogen in a pharmacological carrier together with all other strains previously identified. The process is repeated to ensure all newly appearing pathogenic strains are vaccinated against. The vaccine so produced has been demonstated to be effective in reversal of hard udder syndrome.
    Type: Grant
    Filed: August 31, 1983
    Date of Patent: August 9, 1988
    Assignee: Stolle Research & Development Corporation
    Inventors: Ralph J. Stolle, Lee R. Beck
  • Peptide antibodies and their use in detecting oncogene products
    Patent number: 4762706
    Abstract: Antibodies exhibit specificity toward single amino acid differences between proteins. These antibodies may be produced by synthesizing a peptide of the appropriate amino acid sequence contained in the protein, immunizing a host with the peptide, and extracting sera from the host to obtain the antibodies. The antibodies and the desired protein are then immunoprecipitated under conditions of partial denaturation to expose the epitope of the protein. The antibodies may be used for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: October 17, 1984
    Date of Patent: August 9, 1988
    Assignees: Cetus Corporation, Cold Spring Harbor Laboratories
    Inventors: Francis P. McCormick, Gail L. Wong, Robin Clark, Norman Arnheim, Danute E. Nitecki, James R. Feramisco
  • Immunogenic conjugates
    Patent number: 4761283
    Abstract: An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having a reducing end and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The invention also relates to methods for the preparation of the conjugates, a vaccine containing the conjugates which elicits effective levels of anti-capsular polymer antibodies in humans. Also disclosed are methods for inducing active immunization against systemic infection in young mammals caused by bacterial pathogens comprising the administration of an immunogenic amount of the above-described conjugate.
    Type: Grant
    Filed: March 28, 1986
    Date of Patent: August 2, 1988
    Assignee: The University of Rochester
    Inventor: Porter W. Anderson
  • Multiclass hybrid interferons
    Patent number: 4758428
    Abstract: New multiclass hybrid interferon polypeptides, their corresponding encoding recombinant DNA molecules and transformed hosts which produce the new interferons are described. The amino acid sequences of these hybrids include at least two different subsequences, one of which has substantial homology with a portion of a first class of interferon (e.g., HuIFN-.alpha.) and the other which has substantial homology with a portion of a second class of interferon (e.g., HuIFN-.beta.). Data indicates the interferon activity of .alpha.-.beta. hybrids may be substantially restricted to either cell growth regulatory activity or antiviral activity.
    Type: Grant
    Filed: July 15, 1985
    Date of Patent: July 19, 1988
    Assignee: Cetus Corporation
    Inventors: David F. Mark, Abla A. Creasey